SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001517022-23-000023
Filing Date
2023-08-01
Accepted
2023-08-01 16:05:33
Documents
13
Period of Report
2023-07-26
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K akba-20230726.htm   iXBRL 8-K 31351
  Complete submission text file 0001517022-23-000023.txt   172930

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT akba-20230726.xsd EX-101.SCH 2258
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT akba-20230726_def.xml EX-101.DEF 3783
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT akba-20230726_lab.xml EX-101.LAB 27680
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT akba-20230726_pre.xml EX-101.PRE 14595
7 EXTRACTED XBRL INSTANCE DOCUMENT akba-20230726_htm.xml XML 2718
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36352 | Film No.: 231131655
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences